Home > Research and development > Portfolio

Chagas disease 

Chagas C205 series

objective

Optimize leads issued from the hit-to-lead 205 series, and identify pre-clinical candidates with the potential to fulfill the target product profile for Chagas disease

project start
2017
project status
Completed

last phase of drug development

Discovery project phase
Drug Discovery
Translation project phase
Translational research
clinical trials icon
Clinical trials
Treatment Access
Registration & access

updated 29 Feb 2020

Share on linkedin
Share on twitter
Share on facebook
Share on email
Share on print

Project updates

This series is part of a collaboration agreement made in 2018 with the Drug Discovery Unit of Dundee University in Scotland and GlaxoSmithKline’s Global Health Unit in Spain. With work on the series resulting in a drug candidate for leishmaniasis that will move into translational research, research for a candidate for Chagas from the C205 series is currently on hold.

Partners & service providers

  • AbbVie, USA
  • BioAster, France
  • Charles River Laboratories (formerly WIL Research), France
  • Epichem, Australia
  • Eurofins CEREP, France
  • Griffith University, Australia
  • London School of Hygiene & Tropical Medicine (LSHTM), UK
  • Monash University, Centre for Drug Candidate Optimisation (CDCO), Australia
  • WuXi AppTech, China

Funding

  • Germany - Federal Ministry of Education and Research (BMBF) through KfW
  • Switzerland - Swiss Agency for Development and Cooperation (SDC)
  • The Netherlands - Dutch Ministry of Foreign Affairs (DGIS)
  • UK - UK International Development
  • Médecins Sans Frontières International

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in
Instagram
Twitter
Facebook-f
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

Get in touch

Support us

Work with us